CONMED Stock Price, News & Analysis (NASDAQ:CNMD)

$50.39 -0.41 (-0.81 %)
(As of 12/13/2017 05:54 AM ET)
Previous Close$50.80
Today's Range$49.59 - $51.13
52-Week Range$39.74 - $54.77
Volume240,900 shs
Average Volume126,633 shs
Market Capitalization$1.42 billion
P/E Ratio29.03
Dividend Yield1.55%
Beta0.66

About CONMED (NASDAQ:CNMD)

CONMED logoCONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company's products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company's orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CNMD
CUSIP20741010
Phone315-797-8375

Debt

Debt-to-Equity Ratio0.84%
Current Ratio2.56%
Quick Ratio1.49%

Price-To-Earnings

Trailing P/E Ratio29.03
Forward P/E Ratio27.39
P/E Growth3.26

Sales & Book Value

Annual Sales$763.52 million
Price / Sales1.84
Cash Flow$3.74 per share
Price / Cash13.49
Book Value$20.87 per share
Price / Book2.41

Profitability

Trailing EPS$0.56
Net Income$14.66 million
Net Margins1.99%
Return on Equity8.40%
Return on Assets3.65%

Miscellaneous

Employees3,300
Outstanding Shares27,930,000

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Tuesday, November 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.20 per share on Friday, January 5th. This represents a $0.80 annualized dividend and a yield of 1.59%. The ex-dividend date is Thursday, December 14th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Corporation (NASDAQ:CNMD) issued its earnings results on Thursday, November, 2nd. The medical technology company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.41 by $0.01. The medical technology company had revenue of $190.10 million for the quarter, compared to analyst estimates of $187.13 million. CONMED had a return on equity of 8.40% and a net margin of 1.99%. The business's revenue was up 2.9% on a year-over-year basis. During the same period last year, the business earned $0.41 EPS. View CONMED's Earnings History.

When will CONMED make its next earnings announcement?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED updated its FY17 earnings guidance on Thursday, November, 2nd. The company provided EPS guidance of $1.85-1.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.87.

Where is CONMED's stock going? Where will CONMED's stock price be in 2017?

4 Wall Street analysts have issued twelve-month target prices for CONMED's shares. Their forecasts range from $46.00 to $58.00. On average, they anticipate CONMED's stock price to reach $50.67 in the next twelve months. View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:

  • 1. Needham & Company LLC analysts commented, "We hosted investor meetings in Boston with CNMD’s CEO and CFO earlier this week. We believe that CNMD is making progress in its turnaround, as evidenced by its organic revenue growth of 3% year-to-date (YTD), which is a considerable improvement from the bottom of (3%) growth in 2H14. We expect further improvement in its domestic Orthopedic Surgery business as new products continue to gain momentum and believe that this can push overall revenue growth towards 5%. We also believe that margin expansion will be the next chapter in the CNMD story given higher revenue growth, a reduced currency headwind, and a renewed focus on cost reductions. CNMD’s operating margin is currently around 9% and we see potential for this to reach the mid-teens or higher over time. We think the stock looks undervalued at a P/E of 25.5x our 2018E estimate considering that we think its potential earnings power is $3.00+ per share and we reiterate our Buy rating." (11/17/2017)
  • 2. According to Zacks Investment Research, "Despite exiting the third quarter CONMED on a promising note, declining sales from Orthopedic surgery is a concern. The company operates in a highly competitive environment, adding to our woes. Lower healthcare spending buoyed by the ongoing political conundrum in the U.S. healthcare space is a headwind. CONMED’s stock looks a little overvalued at the moment. However, the stock has outperformed the broader industry in terms of price performance year to date. Strength in General Surgery business on the back of strong performances by Advanced Surgical and Endoscopic Technologies buoys optimism. We are also upbeat about the favorable foreign exchange movements which drove third-quarter sales. Solid revenue guidance is indicative of brighter prospects. CONMED is also benefiting from the increasing trend of using minimally invasive techniques as a large percentage of the company’s products are designed for these procedures." (11/14/2017)

Who are some of CONMED's key competitors?

Who are CONMED's key executives?

CONMED's management team includes the folowing people:

  • Mark E. Tryniski, Independent Chairman of the Board (Age 56)
  • Curt R. Hartman, President, Chief Executive Officer, Director (Age 53)
  • Luke A. Pomilio, Chief Financial Officer, Executive Vice President - Finance (Age 52)
  • Patrick J. Beyer, President of CONMED International (Age 51)
  • Daniel S. Jonas, Executive Vice President - Legal Affairs, General Counsel (Age 53)
  • Heather L. Cohen, Executive Vice President - Human Resources, Secretary (Age 44)
  • Wilfredo Ruiz-Caban, Executive Vice President - Quality Assurance, Regulatory Affairs and Operations (Age 52)
  • Peter K. Shagory, Executive Vice President - Strategy and Corporate Development (Age 48)
  • Nathan Folkert, Vice President, General Manager - U.S. Orthopedics Business (Age 42)
  • John E. Kennedy, Vice President and General Manager - U.S. Endoscopic Technologies (Age 59)

Who owns CONMED stock?

CONMED's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (7.98%), Victory Capital Management Inc. (7.81%), Cramer Rosenthal Mcglynn LLC (3.67%), Macquarie Group Ltd. (2.62%), Fisher Asset Management LLC (2.21%) and Bank of New York Mellon Corp (1.43%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jerome J Lande, Jo Ann Golden, John L Workman, Luke A Pomilio, Mark D Snyder and Mark E Tryniski. View Institutional Ownership Trends for CONMED.

Who sold CONMED stock? Who is selling CONMED stock?

CONMED's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Cramer Rosenthal Mcglynn LLC, Dimensional Fund Advisors LP, Citadel Advisors LLC, Investment Counselors of Maryland LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co. and Stevens Capital Management LP. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, Jo Ann Golden and Luke A Pomilio. View Insider Buying and Selling for CONMED.

Who bought CONMED stock? Who is buying CONMED stock?

CONMED's stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Macquarie Group Ltd., Prudential Financial Inc., Fisher Asset Management LLC, Rothschild Asset Management Inc., Ameriprise Financial Inc., Wells Fargo & Company MN and BT Investment Management Ltd. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen, John L Workman and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy CONMED stock?

Shares of CONMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CONMED stock can currently be purchased for approximately $50.39.

How big of a company is CONMED?

CONMED has a market capitalization of $1.42 billion and generates $763.52 million in revenue each year. The medical technology company earns $14.66 million in net income (profit) each year or $0.56 on an earnings per share basis. CONMED employs 3,300 workers across the globe.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.


MarketBeat Community Rating for CONMED (CNMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CONMED (NASDAQ:CNMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.202.252.33
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.75$48.50$49.33$48.33
Price Target Upside: 6.11% downside9.12% downside0.54% downside0.42% upside

CONMED (NASDAQ:CNMD) Consensus Price Target History

Price Target History for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017Needham & Company LLCReiterated RatingBuy$58.00N/AView Rating Details
11/3/2017KeyCorpReiterated RatingHoldN/AView Rating Details
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/AView Rating Details
4/27/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$50.00 -> $48.00HighView Rating Details
11/23/2016Leerink SwannReiterated RatingHold -> NeutralN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

CONMED (NASDAQ:CNMD) Earnings History and Estimates Chart

Earnings by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ CNMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/30/2018N/AView Earnings Details
11/2/2017Q3 2017$0.41$0.42$187.13 million$190.10 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.41$0.41$194.50 million$197.20 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.35$0.38$181.47 million$186.57 millionViewN/AView Earnings Details
2/1/2017Q416$0.56$0.54$204.04 million$204.10 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.41$180.13 million$184.79 millionViewListenView Earnings Details
7/27/2016Q216$0.46$0.47$191.48 million$193.40 millionViewListenView Earnings Details
4/27/2016Q116$0.41$0.42$180.15 million$181.20 millionViewListenView Earnings Details
1/27/2016Q415$0.51$0.52$191.03 million$191.00 millionViewListenView Earnings Details
10/21/2015Q315$0.44$0.38$173.96 million$169.20 millionViewListenView Earnings Details
7/21/2015Q215$0.44$0.36$182.40 million$181.00 millionViewListenView Earnings Details
4/22/2015Q115$0.41$0.42$176.16 million$177.90 millionViewListenView Earnings Details
1/27/2015Q414$0.54$0.53$196.00 million$195.00 millionViewListenView Earnings Details
10/23/2014Q314$0.39$0.44$173.30 million$175.00 millionViewListenView Earnings Details
7/23/2014Q214$0.47$0.47$190.62 million$188.20 millionViewListenView Earnings Details
4/24/2014Q1$0.47$0.49$191.95 million$181.90 millionViewListenView Earnings Details
2/13/2014Q413$0.49$0.53$197.24 million$203.40 millionViewListenView Earnings Details
10/24/2013Q313$0.40$0.40$186.20 million$179.30 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.44$0.43$193.55 million$193.00 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.45$0.45$196.79 million$187.00 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.50$0.52$200.12 million$201.20 millionViewListenView Earnings Details
10/25/2012$0.40$0.43ViewN/AView Earnings Details
7/26/2012$0.45$0.43ViewN/AView Earnings Details
4/26/2012$0.44$0.43ViewN/AView Earnings Details
2/15/2012$0.39$0.46ViewN/AView Earnings Details
10/27/2011$0.31$0.33ViewN/AView Earnings Details
7/28/2011$0.35$0.35ViewN/AView Earnings Details
4/28/2011$0.31$0.37ViewN/AView Earnings Details
2/3/2011$0.36$0.36ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

CONMED (NASDAQ:CNMD) Earnings Estimates

2017 EPS Consensus Estimate: $1.87
2018 EPS Consensus Estimate: $2.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.30$0.37$0.34
Q2 20172$0.41$0.44$0.43
Q3 20172$0.39$0.40$0.40
Q4 20172$0.70$0.72$0.71
Q1 20181$0.44$0.44$0.44
Q2 20181$0.52$0.52$0.52
Q3 20181$0.47$0.47$0.47
Q4 20181$0.59$0.59$0.59
(Data provided by Zacks Investment Research)

Dividends

CONMED (NASDAQ:CNMD) Dividend Information

Next Dividend:1/5/2018
Annual Dividend:$0.80
Dividend Yield:1.59%
Payout Ratio:142.86% (Trailing 12 Months of Earnings)
43.48% (Based on This Year's Estimates)
40.00% (Based on Next Year's Estimates)
Dividend Payments by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ:CNMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/28/2017quarterly$0.201.48%12/14/201712/15/20171/5/2018
8/29/2017quarterly$0.201.65%9/14/20179/15/201710/5/2017
5/24/2017quarterly$0.201.6%6/13/20176/15/20177/5/2017
2/28/2017quarterly$0.201.92%3/13/20173/15/20174/5/2017
11/21/2016quarterly$0.201.77%12/13/201612/15/20161/5/2017
8/25/2016quarterly$0.201.99%9/13/20169/15/201610/5/2016
5/25/2016quarterly$0.202.05%6/13/20166/15/20167/6/2016
2/23/2016quarterly$0.202.1%3/11/20163/15/20164/5/2016
11/16/2015quarterly$0.201.92%12/11/201512/15/20151/5/2016
8/24/2015quarterly$0.201.53%9/11/20159/15/201510/5/2015
5/29/2015quarterly$0.201.44%6/11/20156/15/20157/6/2015
2/25/2015quarterly$0.201.56%3/12/20153/16/20154/6/2015
11/18/2014quarterly$0.201.92%12/11/201412/15/20141/5/2015
8/25/2014quarterly$0.202.11%9/11/20149/15/201410/6/2014
5/23/2014quarterly$0.201.8%6/12/20146/16/20147/7/2014
2/27/2014quarterly$0.201.72%3/13/20143/17/20144/7/2014
10/28/2013quarterly$0.2012/12/201312/16/20131/6/2014
8/27/2013quarterly$0.151.91%9/12/20139/16/201310/4/2013
5/24/2013quarterly$0.151.76%6/13/20136/17/20137/8/2013
2/27/2013quarterly$0.151.93%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

CONMED (NASDAQ CNMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.62%
Institutional Ownership Percentage: 99.04%
Insider Trades by Quarter for CONMED (NASDAQ:CNMD)
Institutional Ownership by Quarter for CONMED (NASDAQ:CNMD)

CONMED (NASDAQ CNMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2017Luke A PomilioEVPSell29,363$50.70$1,488,704.10View SEC Filing  
11/7/2017Luke A PomilioCFOSell12,429$50.63$629,280.27View SEC Filing  
11/3/2017Luke A PomilioEVPSell10,020$53.57$536,771.40View SEC Filing  
10/3/2017Charles FarkasDirectorBuy148$53.96$7,986.08View SEC Filing  
8/14/2017Jo Ann GoldenDirectorSell3,000$50.00$150,000.00View SEC Filing  
7/5/2017Charles FarkasDirectorBuy157$50.78$7,972.46View SEC Filing  
6/13/2017Dirk KuyperDirectorSell1,000$52.24$52,240.00View SEC Filing  
5/15/2017Daniel JonasEVPSell3,000$51.22$153,660.00View SEC Filing  
4/3/2017Charles FarkasDirectorBuy180$44.41$7,993.80View SEC Filing  
3/13/2017Heather L CohenEVPBuy440$40.00$17,600.00View SEC Filing  
3/10/2017Curt R HartmanCEOBuy8,030$40.11$322,083.30View SEC Filing  
3/6/2017Mark E TryniskiDirectorBuy5,000$41.15$205,750.00View SEC Filing  
1/3/2017Charles FarkasDirectorBuy305$44.65$13,618.25View SEC Filing  
11/8/2016Daniel JonasEVPSell1,500$41.78$62,670.00View SEC Filing  
11/7/2016Daniel JonasEVPSell2,555$40.40$103,222.00View SEC Filing  
10/3/2016Charles FarkasDirectorBuy336$40.04$13,453.44View SEC Filing  
7/1/2016Charles FarkasDirectorBuy282$47.87$13,499.34View SEC Filing  
6/3/2016Luke A PomilioCFOSell4,400$41.56$182,864.00View SEC Filing  
4/1/2016Charles FarkasDirectorBuy338$42.04$14,209.52View SEC Filing  
3/4/2016Mark D SnyderEVPSell2,940$41.32$121,480.80View SEC Filing  
3/2/2016John L WorkmanDirectorBuy2,500$39.85$99,625.00View SEC Filing  
2/19/2016Jerome J LandeDirectorSell1,630,800$38.28$62,427,024.00View SEC Filing  
1/4/2016Charles FarkasDirectorBuy332$42.18$14,003.76View SEC Filing  
12/11/2015David M BronsonDirectorBuy1,500$41.01$61,515.00View SEC Filing  
6/12/2015Jo Ann GoldenDirectorSell1,000$56.03$56,030.00View SEC Filing  
5/29/2015Stephen MandiaDirectorSell14,000$55.62$778,680.00View SEC Filing  
5/6/2015Pat BeyerInsiderBuy5,000$53.36$266,800.00View SEC Filing  
4/30/2015Stephen MandiaDirectorSell3,899$49.97$194,833.03View SEC Filing  
12/12/2014Stephen MandiaDirectorSell4,500$43.23$194,535.00View SEC Filing  
12/1/2014Dirk KuyperDirectorSell1,000$42.85$42,850.00View SEC Filing  
11/19/2014Joseph G DarlingEVPSell4,270$42.00$179,340.00View SEC Filing  
10/29/2014Robert D Shallish JrCFOSell10,410$41.67$433,784.70View SEC Filing  
9/4/2014William AbrahamEVPSell16,062$39.91$641,034.42View SEC Filing  
8/26/2014William AbrahamEVPSell7,423$38.36$284,746.28View SEC Filing  
8/21/2014William AbrahamEVPSell15,986$37.71$602,832.06View SEC Filing  
8/19/2014William AbrahamEVPSell5,312$37.75$200,528.00View SEC Filing  
7/31/2014Curt R HartmanCEOBuy10,000$39.25$392,500.00View SEC Filing  
7/30/2014Bruce DanielsDirectorSell1,600$39.31$62,896.00View SEC Filing  
7/30/2014Joseph J CorasantiCEOSell109,035$39.25$4,279,623.75View SEC Filing  
10/29/2013Joseph J CorasantiCEOSell80,148$36.47$2,922,997.56View SEC Filing  
10/28/2013Bruce DanielsDirectorSell4,500$36.43$163,935.00View SEC Filing  
9/13/2013Joseph CorasantiCEOSell44,852$33.04$1,481,910.08View SEC Filing  
9/11/2013William AbrahamSVPSell7,423$33.48$248,522.04View SEC Filing  
8/15/2013Dirk KuyperDirectorBuy1,000$31.63$31,630.00View SEC Filing  
6/7/2013Daniel JonasVPSell2,000$32.42$64,840.00View SEC Filing  
6/4/2013Heather L CohenVPSell1,200$32.59$39,108.00View SEC Filing  
5/31/2013Luke A PomilioVPSell2,556$33.19$84,833.64View SEC Filing  
5/29/2013Heather L CohenVPSell4,514$34.31$154,875.34View SEC Filing  
5/28/2013Robert D Shallish JrCFOSell10,000$34.35$343,500.00View SEC Filing  
2/15/2013Stuart J SchwartzDirectorSell1,000$30.32$30,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CONMED (NASDAQ CNMD) News Headlines

Source:
DateHeadline
CONMED Corporation (CNMD) Receives Consensus Recommendation of "Hold" from AnalystsCONMED Corporation (CNMD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 8 at 8:06 AM
CONMED Corp. breached its 50 day moving average in a Bearish Manner : CNMD-US : December 5, 2017CONMED Corp. breached its 50 day moving average in a Bearish Manner : CNMD-US : December 5, 2017
finance.yahoo.com - December 5 at 10:06 AM
$212.38 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter$212.38 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter
www.americanbankingnews.com - December 2 at 2:50 AM
$0.65 Earnings Per Share Expected for CONMED Corporation (CNMD) This Quarter$0.65 Earnings Per Share Expected for CONMED Corporation (CNMD) This Quarter
www.americanbankingnews.com - November 30 at 9:32 PM
CONMED Corporation (CNMD) Declares $0.20 Quarterly DividendCONMED Corporation (CNMD) Declares $0.20 Quarterly Dividend
www.americanbankingnews.com - November 28 at 4:40 PM
CONMED Corporation (CNMD) Earns "Buy" Rating from Needham & Company LLCCONMED Corporation (CNMD) Earns "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - November 18 at 11:38 AM
ETFs with exposure to CONMED Corp. : November 16, 2017ETFs with exposure to CONMED Corp. : November 16, 2017
finance.yahoo.com - November 16 at 12:56 PM
CONMED Corporation (CNMD) Stock Rating Upgraded by Zacks Investment ResearchCONMED Corporation (CNMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 14 at 7:20 PM
CONMED Corporation (CNMD) Expected to Announce Quarterly Sales of $211.29 MillionCONMED Corporation (CNMD) Expected to Announce Quarterly Sales of $211.29 Million
www.americanbankingnews.com - November 14 at 9:16 AM
CONMED Corporation (CNMD) Receives Average Recommendation of "Hold" from BrokeragesCONMED Corporation (CNMD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 8:14 AM
CONMED Corporation (CNMD) Expected to Post Earnings of $0.68 Per ShareCONMED Corporation (CNMD) Expected to Post Earnings of $0.68 Per Share
www.americanbankingnews.com - November 12 at 9:30 AM
Insider Selling: CONMED Corporation (CNMD) CFO Sells 12,429 Shares of StockInsider Selling: CONMED Corporation (CNMD) CFO Sells 12,429 Shares of Stock
www.americanbankingnews.com - November 9 at 7:04 PM
Insider Selling: CONMED Corporation (CNMD) EVP Sells 29,363 Shares of StockInsider Selling: CONMED Corporation (CNMD) EVP Sells 29,363 Shares of Stock
www.americanbankingnews.com - November 9 at 6:44 PM
CONMED Corp. :CNMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017CONMED Corp. :CNMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 9:32 PM
Insider Selling: CONMED Corporation (CNMD) EVP Sells 10,020 Shares of StockInsider Selling: CONMED Corporation (CNMD) EVP Sells 10,020 Shares of Stock
www.americanbankingnews.com - November 7 at 3:36 PM
CONMED (CNMD) Q3 Earnings and Revenues Beat, Margin DownCONMED (CNMD) Q3 Earnings and Revenues Beat, Margin Down
finance.yahoo.com - November 6 at 6:39 PM
ETFs with exposure to CONMED Corp. : November 6, 2017ETFs with exposure to CONMED Corp. : November 6, 2017
finance.yahoo.com - November 6 at 6:39 PM
Zacks Investment Research Downgrades CONMED Corporation (CNMD) to SellZacks Investment Research Downgrades CONMED Corporation (CNMD) to Sell
www.americanbankingnews.com - November 6 at 2:54 PM
Leerink Swann Analysts Cut Earnings Estimates for CONMED Corporation (CNMD)Leerink Swann Analysts Cut Earnings Estimates for CONMED Corporation (CNMD)
www.americanbankingnews.com - November 6 at 10:22 AM
CONMED Corporation to Post FY2017 Earnings of $1.86 Per Share, KeyCorp Forecasts (CNMD)CONMED Corporation to Post FY2017 Earnings of $1.86 Per Share, KeyCorp Forecasts (CNMD)
www.americanbankingnews.com - November 6 at 6:36 AM
CONMED Corporation (CNMD) Given Hold Rating at KeyCorpCONMED Corporation (CNMD) Given Hold Rating at KeyCorp
www.americanbankingnews.com - November 4 at 10:37 AM
Edited Transcript of CNMD earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of CNMD earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 7:14 AM
CONMED Corporation (CNMD) Earns Hold Rating from Piper Jaffray CompaniesCONMED Corporation (CNMD) Earns Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - November 3 at 10:46 PM
CONMED Corporation (CNMD) Announces  Earnings ResultsCONMED Corporation (CNMD) Announces Earnings Results
www.americanbankingnews.com - November 2 at 9:29 PM
CONMED Corporation (CNMD) Issues FY17 Earnings GuidanceCONMED Corporation (CNMD) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 2 at 7:32 PM
CONMED Updates 2017 Outlook - Quick FactsCONMED Updates 2017 Outlook - Quick Facts
www.nasdaq.com - November 2 at 6:15 PM
CONMED Corporation to Host Earnings CallCONMED Corporation to Host Earnings Call
finance.yahoo.com - November 2 at 6:15 PM
CONMED Corporation Announces Third Quarter 2017 Financial ResultsCONMED Corporation Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 6:15 PM
CONMED Corporation Announces Retirement of Chief Financial OfficerCONMED Corporation Announces Retirement of Chief Financial Officer
finance.yahoo.com - November 2 at 6:15 PM
Conmed tops Street 3Q forecastsConmed tops Street 3Q forecasts
finance.yahoo.com - November 2 at 6:15 PM
Conmed Corp. Reaches Analyst Target PriceConmed Corp. Reaches Analyst Target Price
www.nasdaq.com - November 2 at 4:15 AM
CONMED Corporation (CNMD) to Release Earnings on ThursdayCONMED Corporation (CNMD) to Release Earnings on Thursday
www.americanbankingnews.com - October 26 at 1:46 AM
$187.07 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter$187.07 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter
www.americanbankingnews.com - October 25 at 6:22 PM
Contrasting CONMED Corporation (CNMD) & Its CompetitorsContrasting CONMED Corporation (CNMD) & Its Competitors
www.americanbankingnews.com - October 14 at 4:28 PM
ETFs with exposure to CONMED Corp. : October 10, 2017ETFs with exposure to CONMED Corp. : October 10, 2017
finance.yahoo.com - October 10 at 6:33 PM
CONMED Corporation to Announce Third Quarter 2017 Financial Results on November 2, 2017CONMED Corporation to Announce Third Quarter 2017 Financial Results on November 2, 2017
finance.yahoo.com - October 10 at 6:33 PM
$187.21 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter$187.21 Million in Sales Expected for CONMED Corporation (CNMD) This Quarter
www.americanbankingnews.com - October 6 at 5:56 AM
CONMED Corp. : CNMD-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 5, 2017CONMED Corp. : CNMD-US: Dividend Analysis : September 15th, 2017 (record date) : By the numbers : October 5, 2017
finance.yahoo.com - October 5 at 11:09 AM
Analyzing NeuroMetrix (NURO) and CONMED Corporation (CNMD)Analyzing NeuroMetrix (NURO) and CONMED Corporation (CNMD)
www.americanbankingnews.com - October 4 at 10:38 AM
Head to Head Review: Orthofix International N.V. (OFIX) versus CONMED Corporation (CNMD)Head to Head Review: Orthofix International N.V. (OFIX) versus CONMED Corporation (CNMD)
www.americanbankingnews.com - October 1 at 2:20 PM
CONMED Corporation (CNMD) Given Average Recommendation of "Hold" by BrokeragesCONMED Corporation (CNMD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 24 at 6:48 AM
Head to Head Contrast: CONMED Corporation (CNMD) vs. The CompetitionHead to Head Contrast: CONMED Corporation (CNMD) vs. The Competition
www.americanbankingnews.com - September 15 at 8:46 PM
CONMED Corp. – Value Analysis (NASDAQ:CNMD) : September 14, 2017CONMED Corp. – Value Analysis (NASDAQ:CNMD) : September 14, 2017
finance.yahoo.com - September 13 at 11:37 PM
CONMED Corp. breached its 50 day moving average in a Bullish Manner : CNMD-US : September 12, 2017CONMED Corp. breached its 50 day moving average in a Bullish Manner : CNMD-US : September 12, 2017
finance.yahoo.com - September 12 at 6:02 PM
CONMED Corporations (CNMD) "Buy" Rating Reiterated at Needham & Company LLCCONMED Corporation's (CNMD) "Buy" Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - September 4 at 10:38 PM
Critical Analysis: CONMED Corporation (CNMD) & K2M Group Holdings (KTWO)Critical Analysis: CONMED Corporation (CNMD) & K2M Group Holdings (KTWO)
www.americanbankingnews.com - August 31 at 6:12 PM
 Brokerages Anticipate CONMED Corporation (CNMD) Will Post Quarterly Sales of $187.21 Million Brokerages Anticipate CONMED Corporation (CNMD) Will Post Quarterly Sales of $187.21 Million
www.americanbankingnews.com - August 30 at 10:00 AM
Critical Review: Meridian Bioscience (VIVO) versus CONMED Corporation (CNMD)Critical Review: Meridian Bioscience (VIVO) versus CONMED Corporation (CNMD)
www.americanbankingnews.com - August 30 at 6:28 AM
Why Is CONMED (CNMD) Down 2.9% Since the Last Earnings Report?Why Is CONMED (CNMD) Down 2.9% Since the Last Earnings Report?
www.nasdaq.com - August 29 at 5:45 PM
CONMED Corporation (CNMD) Announces Quarterly Dividend of $0.20CONMED Corporation (CNMD) Announces Quarterly Dividend of $0.20
www.americanbankingnews.com - August 29 at 4:48 PM

SEC Filings

CONMED (NASDAQ:CNMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CONMED (NASDAQ:CNMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CONMED (NASDAQ CNMD) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.